The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma.
We treated 17 patients with localized, nasal NK/T-cell lymphoma with two cycles of dose-intense CHOP (DI-CHOP) and early involved field radiation (IFRT). Sixteen out of 17 patients were evaluable for response. After two cycles of DICHOP, nine patients achieved complete remission (CR) (53%) and six had partial remissions (35%). After IFRT, 13 patients achieved CR (CR rate 76%; 95% CI, 56%-96%). The 3-year progression-free and overall survival rates were 56%, and 67%, respectively. This study shows that anthracycline-based chemotherapy seems to be ineffective in decreasing systemic failure even when administered at maximal dose intensity.
Lee
Se-Hoon
SH
Ahn
Yong Chan
YC
Kim
Won Seog
WS
Ko
Young H
YH
Kim
Kihyun
K
Park
Keunchil
K
D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000473:pathology* / Q000528:radiation effects; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D011241:Prednisone / Q000008:administration & dosage; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D018943:Anthracyclines; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone